Annexon grabs $75M to pay for push into PhII studies for C1q drugs
Back when Bain’s Ricky Sun worked at Biogen, he gained a deep appreciation for the role of the classical complement pathway in neurodegeneration. And now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.